News
We send the latest information from SMC Laboratories.
Genomics Institute of the Novartis Research Foundation’s publication on Journal of Medicinal Chemistry
SMC announces that Genomics Institute of the Novartis Research Foundation has published the results of a study using STAM™ model in Journal of Medicinal Chemistry. Title: “Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis” Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis | Journal of Medicinal…
Can-Fite BioPharma’s publication on International Journal of Molecular Medicine
SMC announces that Can-Fite BioPharma has published the results of a study using STAM™ model in International Journal of Molecular Medicine. Title: “The A3 adenosine receptor agonist, namodenoson, ameliorates non-alcoholic steatohepatitis in mice” The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice (spandidos-publications.com)
Pfizer’s publication on Science Translational Medicine.
SMC announces that Pfizer has published the results of a study using STAM™ model in Science Translational Medicine. Title: “Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis” Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis | Science Translational Medicine (sciencemag.org)
ChemomAb’s publication on JHEP Reports.
SMC announces that ChemomAb has published the results of a study using STAM™ model in JHEP Reports. Title: “A Blocking Monoclonal Antibody to CCL24 Alleviates Liver Fibrosis and Inflammation in Experimental Models for Liver Damage” A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage – ScienceDirect…
Enzychem Lifesciences Corporation’s presentation at AASLD The Liver Meeting® 2019 in Boston.
SMC announced that Enzychem Lifesciences Corporation presented results of a study using STAM™ model at poster presentation at AASLD The Liver Meeting® 2019 in Boston, MA, November 8-12, 2019. Title: “EC-18, a novel immune resolution accelerator, improves NASH and liver fibrosis”
Enyo Pharma SA’s presentation at AASLD The Liver Meeting® 2019 in Boston.
SMC announced that Enyo Pharma SA presented results of a study using STAM™ model at poster presentation at AASLD The Liver Meeting® 2019 in Boston, MA, November 8-12, 2019. Title: “In vitro and in vivo characterization of EYP001 a novel, potent and selective FXR agonist now in a phase 2 clinical trial in NASH”
Dr. Falk Pharma GmbH’s presentation at AASLD The Liver Meeting® 2019 in Boston.
SMC announced that Dr. Falk Pharma GmbH presented results of a study using STAM™ model at poster presentation at AASLD The Liver Meeting® 2019 in Boston, MA, November 8-12, 2019. Title: “Norursodeoxycholic acid (norUDCA) significantly ameliorates liver injury in the STAM mouse model for non-alcoholic steatohepatitis (NASH)”
NeuroVive Pharmaceutical’s publication on Cells.
SMC announced that NeuroVive Pharmaceutical has published the results of a study using STAM™ model on International Journal of Molecular Sciences. Title: “Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis”
Dokkyo Medical University’s publication on International Journal of Molecular Sciences.
SMC announced that Dokkyo Medical University has published the results of a study using STAM™ model on International Journal of Molecular Sciences. Title: “The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma”
FDA-National Center for Toxicological Research’s publication on Toxicological Sciences.
SMC announced that FDA-National Center for Toxicological Research has published the results of a study using STAM™ model on Toxicological Sciences. Title: “Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis”